Testing effectiveness (Phase 2)Study completedNCT00606307
What this trial is testing
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Who this might be right for
Myeloproliferative Diseases
Italfarmaco 29